SCIENTURE HOLDINGS, INC. , a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC’s commercial operations. Under Ms. Rath’s leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercial Services, LLC (“Syneos Health”), a premier biopharmaceutical solutions organization, by executing a Master Commercial Services Agreement with Syneos Health (the “MCSA”). Pursuant to the MCSA, Syneos Health will serve as Scienture, LLC’s Contract Sales Organization (CSO). This collaboration is set to enhance Scienture, LLC’s commercial capabilities and expand its market reach through Syneos Health’s proven expertise in outsourced sales solutions.
Health Technology Insights: PathAI Expands AISight Digital Pathology Adoption with Four New Laboratory Partners
Ms. Rath, who joined Scienture in a full time capacity on November 1, 2024, brings over 20 years of industry experience, having previously served in key leadership roles at Pfizer, CVS Caremark and Aurobindo Pharma. With a proven track record in driving sales strategy, strategic marketing, sales operations and market access, she will spearhead Scienture, LLC’s commercial initiatives, focusing on revenue growth, strategic partnerships, and customer engagement.
Additionally, Scienture, LLC will leverage Syneos Health’s comprehensive suite of commercial services to drive greater awareness of Scienture, LLC’s products. This includes field sales, inside sales, and customer and tech-enabled engagement strategies. All will be unperpinned by the predictive and adaptive analytics capabilities of Syneos Health’s Kinetic platform designed to connect, harmonize and streamline end-to-end commercial solutions.
“We are thrilled to have Michele as part of our leadership team,” said Narasimhan Mani, Ph.D., MBA, President of Scienture, LLC. “Her deep expertise in commercial operations will be instrumental in the upcoming launches of our two FDA-approved brand products Arbli (losartan potassium) oral suspension and Rezenopy (naloxone HCl) nasal spray. In addition, by leveraging Syneos Health’s expansive network and an innovative sales model, Scienture, LLC is well-positioned to accelerate our growth and better serve our customers.”
Health Technology Insights: Sensitek and GRTHealth Partner to Revolutionize Aging-in-Place
“We are very pleased to have Michele Rath as our CCO. She is a great addition to our executive team,” added Shankar Hariharan, Ph.D., CEO of Scienture, LLC. “Establishing a relationship with Syneos Health is a pivotal step in strengthening our commercial presence and optimizing our go-to-market strategy. By combining our innovative offerings with Syneos’ specialized sales expertise, we will be well-positioned to maximize our market potential.”
“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored sales strategies and deep industry insights to support Scienture in achieving its strategic vision and business goals.”
Health Technology Insights: HealthLynked Enhances Patient Booking and Upgardes to ARi Assistant
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – GlobalNewswire
